Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study

被引：0
|
作者：
Hanfang Jiang
Huiping Li
Guohong Song
Lijun Di
Bin Shao
Ying Yan
Xiaoran Liu
Yifei Chen
Ruyan Zhang
Ran Ran
Yaxin Liu
Xinyu Gui
Nan Wang
Huan Wang
机构：
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology
来源：
Breast Cancer Research and Treatment | 2023年 / 199卷
关键词：
Pegylated liposomal doxorubicin; Metastatic breast cancer; HER2-negative; Efficacy; Safety;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：67 / 79
页数：12
相关论文
共 50 条
  • [1] Pegylated liposomal doxorubicin (Duomeisu®) monotherapy in patients with HER2-negative metastatic breast cancer heavily pretreated with anthracycline and taxanes: a single-arm, phase II study
    Jiang, Hanfang
    Li, Huiping
    Song, Guohong
    Di, Lijun
    Shao, Bin
    Yan, Ying
    Liu, Xiaoran
    Chen, Yifei
    Zhang, Ruyan
    Ran, Ran
    Liu, Yaxin
    Gui, Xinyu
    Wang, Nan
    Wang, Huan
    BREAST CANCER RESEARCH AND TREATMENT, 2023, 199 (01) : 67 - 79
  • [2] Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naive and anthracycline pretreated metastatic breast cancer patients
    Fabi, A
    Ferretti, G
    Papaldo, P
    Salesi, N
    Ciccarese, M
    Lorusso, V
    Carlini, P
    Carpino, A
    Mottolese, M
    Cianciulli, AM
    Giannarelli, D
    Sperduti, I
    Felici, A
    Cognetti, F
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (05) : 615 - 623
  • [3] Biweekly Pegylated Liposomal Doxorubicin (Caelyx) in Heavily Pretreated Metastatic Breast Cancer: A Phase 2 Study
    Jehn, Christian F.
    Hemmati, Philipp
    Lehenbauer-Dehm, Silvia
    Kuemmel, Sherko
    Flath, Bernd
    Schmid, Peter
    CLINICAL BREAST CANCER, 2016, 16 (06) : 514 - 519
  • [4] Pegylated liposomal doxorubicin in combination with gemcitabine: a phase II study in anthracycline-naïve and anthracycline pretreated metastatic breast cancer patients
    Alessandra Fabi
    Gianluigi Ferretti
    Paola Papaldo
    Nello Salesi
    Mariangela Ciccarese
    Vito Lorusso
    Paolo Carlini
    Armando Carpino
    Marcella Mottolese
    Anna Maria Cianciulli
    Diana Giannarelli
    Isabella Sperduti
    Alessandra Felici
    Francesco Cognetti
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 615 - 623
  • [5] An open-label, single-arm, multicenter, phase II trial of bireociclib as monotherapy for heavily pretreated HR-positive, HER2-negative advanced breast cancer patients: BRIGHT-1 trial
    Wang, Jiayu
    Zhang, Qingyuan
    Sun, Tao
    Li, Huiping
    Cheng, Ying
    Tong, Zhongsheng
    Li, Huihui
    Li, Wei
    Wang, Jingfen
    Teng, Yuee
    Wu, Xinhong
    Cheng, Jing
    Chen, Zhendong
    Zhu, Zhengqiu
    Wang, Li
    Liu, Mingming
    Duan, Xianghui
    Xu, Lingmei
    Xu, Binghe
    CANCER COMMUNICATIONS, 2025,
  • [6] Pyrotinib combined with metronomic etoposide in heavily pretreated HER2-positive metastatic breast cancer: a single-arm, phase II study
    Liu, Jiaxuan
    He, Maiyue
    Jiang, Mingxia
    Zhou, Shihan
    Zhang, Mengqi
    Li, Yiqun
    Chen, Shanshan
    Cai, Ruigang
    Mo, Hongnan
    Lan, Bo
    Ma, Fei
    Xu, Binghe
    Li, Qiao
    BMC CANCER, 2024, 24 (01)
  • [7] Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2positive breast cancer: A phase II single-arm study
    Yang, Yaping
    Jin, Liang
    Li, Yudong
    Rao, Nanyan
    Gong, Chang
    Li, Shunrong
    Wu, Jiannan
    Zhao, Jinghua
    Ding, Linxiaoxiao
    Gan, Fengxia
    Zhang, Jun
    Feng, Ruifa
    Liu, Zhenzhen
    Liu, Qiang
    CHINESE JOURNAL OF CANCER RESEARCH, 2024, 36 (01)
  • [8] Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study
    Ortega, Vanesa
    Anton, Antonio
    Garau, Isabel
    Afonso, Nomia
    Calvo, Lourdes
    Fernandez, Yolanda
    Martinez-Garcia, Maria
    Blanco, Esperanza
    Zamora, Pilar
    Garcia, Mirta
    Juan Illarramendi, Jose
    Rodriguez Sanchez, Csar Augusto
    Sampayo, Miguel
    Aguirre, Elena
    Manuel Perez-Garcia, Jose
    Cortes, Javier
    Llombart-Cussac, Antonio
    CLINICAL BREAST CANCER, 2019, 19 (02) : 105 - 112
  • [9] Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-Overexpressing metastatic breast cancer
    Andreopoulou, Eleni
    Gaiotti, Darci
    Kim, Eugene
    Volm, Matthew
    Oratz, Ruth
    Freedberg, Robin
    Downey, Andrea
    Vogel, Charles L.
    Chia, Stephen
    Muggia, Franco
    CLINICAL BREAST CANCER, 2007, 7 (09) : 690 - 696
  • [10] Combination of pegylated liposomal doxorubicin plus gemcitabine in heavily pretreated metastatic breast cancer patients: Long-term results from a single institution experience
    Martin-Romano, Patricia
    Baraibar, Iosune
    Espinos, Jaime
    Legaspi, Jairo
    Lopez-Picazo, Jose M.
    Manuel Aramendia, Jose
    Fernandez, Oscar A.
    Santisteban, Marta
    BREAST JOURNAL, 2018, 24 (04) : 473 - 479
12345